A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
Study sponsor: Agios Pharmaceuticals, Inc. · AGIO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-11-13Actual
Enrollment · participants194Actual
Source updated2026-10-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.